GRPEL2

Across TCGA pan-cancer cohorts, GRPEL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRPEL2 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GRPEL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GRPEL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where GRPEL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.977	0.649	.003	39	view →
PDAC	OS	Tertile	All	0.241	0.662	.009	25	view →
CCRCC	DFS	Tertile	All	0.745	0.968	.001	24	view →
LSCC	DFS	Tertile	II,III,IV	0.863	0.387	<.001	24	view →
LUAD	DFS	Median	II,III,IV	0.217	0.769	.010	16	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GRPEL2–HNSC (OS)

Open the HNSC breakdown →